Logopenic progressive aphasia (LPA) is a variant of primary progressive aphasia. It is defined clinically by impairments in naming and sentence repetition. It is similar to conduction aphasia and is associated with atrophy to the left posterior temporal cortex and inferior parietal lobule. It is suspected that an atypical form of Alzheimers disease is the most common cause of logopenic progressive aphasia.Although patients with the logopenic variant of PPA are still able to produce speech, their speech rate may be significantly slowed due to word retrieval difficulty. Over time, they may experience the inability to retain lengthy information, causing problems with understanding complex verbal information. Some additional behavioral features include irritability, anxiety and agitation.Compared to other subtypes of primary progressive aphasia, the logopenic variant has been found to be associated with cognitive and behavioral characteristics. Studies have shown that patients with the logopenic variant perform significantly worse on tests of calculation than other primary progressive aphasia patients. Several logopenic variant patients, especially those with Alzheimers disease pathology, have also been found to perform poorly on memory tasks.Logopenic progressive aphasia is caused by damage to segregated brain regions, specifically the inferior parietal lobe and superior temporal regions. Difficulties in naming are produced from the thinning of the inferior parietal lobe. Damage to the dorsal pathways creates language deficiency in patients that is characteristic of logopenic progressive aphasia. See also
Aphasia
Dementia
Early-onset Alzheimers disease

References
Further reading
Harciarek M, Kertesz A (September 2011). "Primary progressive aphasias and their contribution to the contemporary knowledge about the brain-language relationship". Neuropsychol Rev. 21 (3): 271–87.
Screening
Metabolic disorder screening can be done in newborns via blood, skin, or hearing tests. Management
Metabolic disorders can be treatable by nutrition management, especially if detected early. It is important for dieticians to have knowledge of the genotype to create a treatment that will be more effective for the individual. See also
Metabolic syndrome
Metabolic Myopathies
Lysosomal storage disease
Deficiency disease
Hypermetabolism

References
Further reading
Hoffmann, Georg F.; Zschocke, Johannes; Nyhan, William L. (21 November 2009). Inherited Metabolic Diseases: A Clinical Approach. Springer. ISBN 9783540747239. Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu YH, Harris KA, Kris-Etherton P, Kushner R, Molini-Blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT, American Association of Clinical Endocrinologists, American College of Endocrinology and the Obesity Society (September–October 2013). "Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society". Endocr Pract. 19 (Suppl 3): 1–82. doi:10.4158/EP13155.GL. PMID 24129260. Archived from the original on 4 March 2016. Retrieved 27 July 2015. External links
"Metabolic disorders". KidsHealth.org. Retrieved 27 July 2015.